ICAR

Zap Energy secures power supply manufacturing capabilities with acquisition of liquidated ICAR assets

Retrieved on: 
Wednesday, June 14, 2023
Engineering, Manufacturing, Alternative Energy, Energy, Research, Science, Nuclear, Zap, Ignition, Systems engineering, Plasma, Zap Energy, Acquisition, ICAR, Multimedia, Specialization, Management

Zap Energy announced today that it has acquired a substantial package of liquidated assets from ICAR, formerly a leading global manufacturer of capacitors and power supply equipment.

Key Points: 
  • Zap Energy announced today that it has acquired a substantial package of liquidated assets from ICAR, formerly a leading global manufacturer of capacitors and power supply equipment.
  • View the full release here: https://www.businesswire.com/news/home/20230613579409/en/
    Zap Energy has purchased the assets of ICAR, a global capacitor manufacturer.
  • Specialized equipment like the automatic winding machine shown here will be used to advance and scale Zap’s fusion energy technologies.
  • The equipment acquired by Zap from Italy-based ICAR represents the majority of the company’s global manufacturing line.

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
Wednesday, April 12, 2023
Bemnifosbuvir, Truncation, Therapy, Hospital, Virology, Dengue virus, COVID-19, Atea, Pharmacokinetics, Viral, ICAR, QRS, Doctor of Philosophy, QT, QT interval, Plasma, Congress, ECCMID, International Conference on Population and Development, Antiviral Research, Patient, European, Risk, Political moderate, Adolescence, Electrocardiography, Heart rate, Conference, HCV, Infection, Safety, Pharmaceutical industry

These results are being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which is taking place April 15-18, 2023 in Copenhagen, Denmark.

Key Points: 
  • These results are being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which is taking place April 15-18, 2023 in Copenhagen, Denmark.
  • “The MORNINGSKY data also highlight additional potential clinical benefits of bemnifosbuvir.
  • Adverse events leading to treatment discontinuation were observed in 2.8% of patients treated with bemnifosbuvir compared to 7% of patients receiving placebo.
  • Atea will also present clinical data for AT-752, an oral double prodrug of a guanosine nucleotide analog for the treatment of dengue virus, at ECCMID 2023.

AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 3, 2023
Well, Pancreatic cancer, Society, AIM, Therapy, British Society for Haematology, RNA, COVID-19, Ebola, Erasmus MC, Viral, ICAR, Research, Doctor of Philosophy, AstraZeneca, International Conference on Population and Development, Antiviral Research, Patient, DSM-IV codes, Cancer, Rintatolimod, Immunology, Conference, NYSE, Pharmaceutical industry, Cryptocurrency

OCALA, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today reported its financial results for the fourth quarter and full year 2022 and provided a business update. As previously announced, the Company will host its inaugural conference call and audio webcast, today, Monday, April 3, 2023, at 8:30 AM ET (details below).

Key Points: 
  • Our team is committed to the development of Ampligen for unmet medical needs in cancers, immune disorders and viral diseases.
  • AIM’s goal is to generate near- and long-term value for all stockholders,” commented Thomas K. Equels, Chief Executive Officer of AIM.
  • As of December 31, 2022, AIM reported cash and cash equivalents of $34.2 million, compared to $48.3 million as of December 31, 2021.
  • Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call.

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

Retrieved on: 
Thursday, March 16, 2023
Research, Conference, United States Army Medical Research Institute of Infectious Diseases, Mortality, Tropical disease, NYSE, RNA, Viral, Environmental science, Manuscript, University of Cagliari, International Conference on Emerging Infectious Diseases, ICAR, Ebola, Laboratory, AIM, Human, TLR3, PAMP, COVID-19, FDA, Disease, European Medicines Agency, Antiviral Research, EBOV, Doctor of Philosophy, Orphan drug, EVD, Investigational New Drug, Cancer, DSM-IV codes, Therapy, University, Vaccine, Pharmaceutical industry, Central Africa, Rintatolimod

Highlights of the recently published Ampligen data that was presented include:

Key Points: 
  • Highlights of the recently published Ampligen data that was presented include:
    As a TLR3 agonist, Ampligen induces and enhances innate immunological responses to EBOV infection.
  • AIM CEO Thomas K. Equels commented, “In vivo pre-clinical analysis shows that Ampligen has potential as both a prophylactic and an early-onset therapeutic in Ebola virus disease.
  • Animal studies with Ampligen at the United States Army Medical Research Institute of Infectious Diseases Biosafety Level 4 laboratories demonstrated 100% protective survival, as compared to 100% mortality in Ebola virus disease.
  • Ultimately, the Company's goal is to seek a Tropical Disease Priority Review Voucher for new drug applications associated with these indications.

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023
Poster, Conference, Ensitrelvir, Enzyme assay, Viral, Novel, Pan, SARS-CoV-2, Arbutus, International Conference on Emerging Infectious Diseases, Gesellschaft mit beschränkter Haftung, ICAR, Dodi Protero, Virology, Antiviral Research, EC50, Omicron, Therapy, IND, Pharmaceutical industry, Vaccine, Mpro

WARMINSTER, Pa., March 14, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that preclinical data for AB-343, our novel oral SARS-CoV-2 Mpro inhibitor, has been presented in poster format at the 36th International Conference on Antiviral Research (ICAR), in Lyon, France.

Key Points: 
  • “We are excited that our preclinical data for AB-343 has been selected for poster presentation at ICAR.
  • Many of the studies compared AB-343 to nirmatrelvir, the active ingredient in Pfizer’s Paxlovid™ and ensitrelvir, the active ingredient in Shionogi’s Xocova®.
  • The results showed that AB-343 targets SARS-CoV-2 Mpro and inhibits viral replication in vitro (EC50 ~ 20nM).
  • Some of these studies were conducted in part with Proteros biostructures GmbH under the discovery research and license agreement entered into in April 2021.

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023
Conference, Na'aran, Viral, RNA-dependent RNA polymerase, International Conference on Emerging Infectious Diseases, CNRS, ICAR, COVID-19, SLC, Rat, Doctor of Philosophy, CYP450, Urine, HIV disease progression rates, Cirrhosis, ABC, Antiviral Research, CET, SP, Drug resistance, Aix-Marseille University, SARS-CoV-2, Fever Dream, NS5A, BEM, Infection, Sulfur, Plasma, GUK1, Risk, ADME, Methylation, Enzyme, Patient, Metabolism, UGT1A1, Coronavirus, Phosphate, Safety, Discovery and development of NS5A inhibitors, RNA, Hepatitis C, Human coronavirus OC43, Combination, Virus, DENV, Maintenance, Architecture, GalNAc-T activation pathway, Feces, HINT1, Orthornavirae, Dengue virus, RZR, Therapy, NS5, Pharmaceutical industry, Vaccine, Flour, Phosphorus, Bemnifosbuvir, HCV

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for serious viral diseases, today announced the presentation of new Phase 1, in vitro and in vivo data that demonstrate key profile attributes of Atea’s lead drug candidate, bemnifosbuvir, for the treatment of COVID-19 and hepatitis C (HCV). Additionally, new data for AT-752 for dengue and a nucleotide analogue are being presented. These results are being presented at the 36th International Conference on Antiviral Research (ICAR 2023) taking place March 13-17, 2023 in Lyon, France.

Key Points: 
  • Additionally, new data for AT-752 for dengue and a nucleotide analogue are being presented.
  • These results are being presented at the 36th International Conference on Antiviral Research (ICAR 2023) taking place March 13-17, 2023 in Lyon, France.
  • These advantages include a higher barrier to resistance and maintenance of antiviral activity in the presence of COVID-19 variants.
  • Additionally, the combination of bemnifosbuvir and ruzasvir for the treatment of HCV demonstrated potent in vitro synergistic antiviral activity and in vivo preclinical safety without adverse interactions.

Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Molecule, Tissue, Ferret, RNA-dependent RNA polymerase, Omicron, Oral, Pharmacokinetics, Into, MAD, Animal, Irrigation, Mitigation, CET, Heart, Antiviral Research, Potential, Conference, SARS-CoV-2, Plasma, ID, PK, SAD, C24, Patient, Treatment, Adipocyte, RNA, International Conference on Emerging Infectious Diseases, PBO, Medication, Rat, Safety, Half-life, Gland, Viral, ICAR, IC50, COVID-19, UTP, Headache, Pharmaceutical industry, Vaccine, Powder metallurgy, Phosphorus

Additional preclinical data show EDP-235’s targeted tissue penetration and potential to mitigate rebound in COVID-19 patients.

Key Points: 
  • Additional preclinical data show EDP-235’s targeted tissue penetration and potential to mitigate rebound in COVID-19 patients.
  • Additional preclinical data demonstrate that EDP-235’s optimized tissue targeting may help to minimize viral rebound.
  • To evaluate the impact of EDP-235 treatment on SARS-CoV-2 transmission, infected source animals were co-housed with uninfected contact animals 60 hours post-infection.
  • This high throughput screen identified multiple, structurally diverse, non-nucleoside SARS-CoV-2 RdRp inhibitors as potential starting points for hit optimization.

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research

Retrieved on: 
Wednesday, March 8, 2023
Discovery and development of NS5A inhibitors, GalNAc-T activation pathway, Infection, HCV, Conference, Antiviral Research, Therapy, RZR, BEM, ICAR, SARS-CoV-2, International Conference on Emerging Infectious Diseases, Combination, Viral, Pharmaceutical industry, Vaccine

BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for several viral diseases, today announced six upcoming presentations at the 36th International Conference on Antiviral Research (ICAR), which will take place March 13-17, 2023 in Lyon, France.

Key Points: 
  • BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for several viral diseases, today announced six upcoming presentations at the 36th International Conference on Antiviral Research (ICAR), which will take place March 13-17, 2023 in Lyon, France.
  • Presentation details are as follows:
    Title: The Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR), the HCV NS5B and NS5A Inhibitors, Demonstrates Potent In Vitro Synergistic Antiviral Activity and In Vivo Preclinical Safety Without Adverse Interactions
    Title: Five Cellular Enzymes in the Activation Pathway of Bemnifosbuvir, a Drug-Candidate Against SARS-CoV-2 Infections

Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research

Retrieved on: 
Wednesday, March 8, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Research, Science, Biotechnology, Treatment, ICAR, Mitigation, Viral, CET, International Conference on Emerging Infectious Diseases, SARS-CoV-2, Potent, Antiviral Research, Conference, Potential, Tissue, Medication, Pharmaceutical industry, Vaccine, Powder metallurgy

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor in development as an oral, once-daily treatment for COVID-19, will be presented at the 36th International Conference on Antiviral Research (ICAR) being held March 13-17, 2023 at the Centre De Congres De Lyon (Lyon Convention Center) in Lyon, France.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor in development as an oral, once-daily treatment for COVID-19, will be presented at the 36th International Conference on Antiviral Research (ICAR) being held March 13-17, 2023 at the Centre De Congres De Lyon (Lyon Convention Center) in Lyon, France.
  • New clinical data being highlighted include results from a Phase 1 study of EDP-235.
  • Additionally, new preclinical findings regarding EDP-235’s effect on replication and transmission, as well as its potential to mitigate viral rebound, will be presented.
  • Further information about ICAR 2023 can be found here .

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Tuesday, February 7, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Chronic obstructive pulmonary disease, ECCMID, Human, Viral load, Fiscal, ICAR, Half-life, SARS-CoV-2, Epidemiology, PK, International Society for Antiviral Research, Omicron, Upper respiratory tract infection, Data, Virus, Viral, Animal, Safety, RSV, Patient, Asthma, Housing, Ritonavir, HBV, Risk, Virology, European Congress of Mathematics, Congress, Ferret, HCV, Heart, Infection, Research, International Conference on Emerging Infectious Diseases, Antiviral Research, Conference, European, Pharmacokinetics, Medication, Pharmaceutical industry, Cryptocurrency, Video game, Vaccine, Perfume, SPRINT

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal first quarter ended December 31, 2022.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal first quarter ended December 31, 2022.
  • For the three months ended December 31, 2021, total royalty revenue was $27.6 million on AbbVie’s sales of MAVYRET/MAVIRET.
  • The decline is primarily a result of continued lower treated patient volumes due to the COVID-19 pandemic.
  • Research and development expenses totaled $40.9 million for the three months ended December 31, 2022, compared to $48.5 million for the three months ended December 31, 2021.